Advertisement

Pharmaceutical Medicine

, Volume 23, Issue 5–6, pp 263–267 | Cite as

Preparing for Regulatory Review and Reimbursement Decisions

A Case for Cooperation between Regulatory Authorities, Sponsors and Health Technology Assessment Agencies
  • Lawrence E. Liberti
  • Franz Pichler
  • Stuart R. Walker
Editorial

The process of drug discovery, development and regulation has been described as a series of incremental advancements punctuated by periodic, radically innovative paradigm shifts.[1] Keystone advancements in this modern phase of medicines discovery have included the refinement of targeted combinatorial chemistry, the practical application of high-throughput screening technologies, advances in data mining and bioinformatics, and the use of proteomics and biomarkers from the earliest phases of discovery and throughout the development lifecycle.

Advances in standardizing regulatory requirements promulgated by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) have led to ways to achieve greater harmonization in the interpretation and application of technical guidelines and requirements for product registration with the objective of reducing or obviating the need to duplicate the testing carried out during the...

Notes

Acknowledgements

This article benefited from the review of Dr Mel Walker, GlaxoSmithKline. The authors also acknowledge the inclusion of concepts presented by Dr Eric Abadie, Committee for Medicinal Products for Human Use at the European Medicines Agency; Dr Hilary Malone, Wyeth Laboratories; Clare McGrath, Pfizer Laboratories; Professor Robert Peterson, University of British Columbia; and Dr Ad Shuurman, Medicine Evaluation Committee at the workshop entitled “Review and reimburse-ment: a special case for better co-operation” held 29–30 September 2009, Surrey, UK, and sponsored by the Institute (http://www.cmr.org

References

  1. 1.
    Attridge J. Innovation models and their application to the pharmaceutical sector. 2006; discussion paper 2: 1–19 [online]. Available from URL: http://www3.imperial.ac.uk/portal/pls/portallive/docs/1/7290711.PDF [Accessed 2009 Nov 27]Google Scholar
  2. 2.
    International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. History and future of ICH [online]. Available from URL: http://www.ich.org/cache/compo/276-254-1.html [Accessed 2009 Nov 27]
  3. 3.
    Hunter AJ. The innovative medicines initiative: a pre-competitive initiative to enhance the biomedical science base of Europe to expedite the development of new medicines for patients. Drug Discov Today 2008; 13: 371–3PubMedCrossRefGoogle Scholar
  4. 4.
    United States Food and Drug Administration. FDA critical path initiative announcement [online]. Available from URL: http://www.trialstransformation.org/fda-critical-path-initiative-press-release/ [Accessed 2009 Nov 27]
  5. 5.
    Siva N. The drug price is right: or is it? Lancet 2009; 373: 1326–7PubMedCrossRefGoogle Scholar
  6. 6.
    Eichler HG. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nat Rev Drug Discov 2008; 7: 818–26PubMedCrossRefGoogle Scholar
  7. 7.
    Breckenridge A, Walley T. Early access to medicines. Clin Pharm Ther 2008; 84: 23–5Google Scholar
  8. 8.
    Strom BL. How the US drug safety system should be changed. JAMA 2006; 295: 2072–5PubMedCrossRefGoogle Scholar
  9. 9.
    Lucas F, Easley C. A focus on commercial innovation and risk sharing. Axiom Dig 2009; 9–11 [online]. Available from URL: http://www.popewoodhead.com/downloads/Axiom_Digest_09.pdf [Accessed 2009 Nov 27]Google Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Lawrence E. Liberti
    • 1
  • Franz Pichler
    • 1
  • Stuart R. Walker
    • 1
  1. 1.CMR International Institute for Regulatory ScienceThe Johnson BuildingLondonUK

Personalised recommendations